Molecular imaging of angiogenesis with SPECT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue SUPPL. 1, 2010, Pages

  Dijkgraaf, Ingrid ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

v 3; Angiogenesis; ECM; PMSA; VEGF

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BEVACIZUMAB IN 111; BEVACIZUMAB ZR 89; BIOTIN INACTIVATED VASCULOTROPIN TC 99M; FIBRONECTIN; HUMAN TRANSFERRIN VASCULOTROPIN TC 99M; HYNIC ARGINYLGLYCYLASPARTIC ACID TC 99M; HYNIC VASCULOTROPIN TC 99M; INDIUM 111; NC 100692 TC 99M; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; RANIBIZUMAB IN 111; SCLEROPROTEIN; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 121 I 123; VASCULOTROPIN 145; VASCULOTROPIN 162; VASCULOTROPIN 165; VASCULOTROPIN 165 I 123; VASCULOTROPIN 165B; VASCULOTROPIN 183; VASCULOTROPIN 189; VASCULOTROPIN 206; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; BINDING AFFINITY; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CAMERA; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; GAMMA RADIATION; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; LIVER METASTASIS; LUNG CANCER; MELANOMA; MICROSPECTROPHOTOMETRY; MOLECULAR IMAGING; NEOVASCULARIZATION (PATHOLOGY); POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTEGRIN ALPHAVBETA3; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77956267478     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1499-9     Document Type: Review

References (77)

1. N Ferrara 2000 Vascular endothelial growth factor and the regulation of angiogenesis Recent Prog Horm Res 55 15 35 1:CAS:528:DC%2BD3MXitVGqsrs%3D 11036931
2. M Kuwano J Fukushi M Okamoto A Nishie H Goto T Ishibashi, et al. 2001 Angiogenesis factors Intern Med 40 565 572 10.2169/internalmedicine.40.565 1:CAS:528:DC%2BD3MXntFGgt7Y%3D 11506294
3. LM Ellis W Liu SA Ahmad F Fan YD Jung RM Shaheen, et al. 2001 Overview of angiogenesis: biologic implications for antiangiogenic therapy Semin Oncol 28 94 104 10.1016/S0093-7754(01)90287-8 1:CAS:528:DC%2BD3MXpt1Wnsr8%3D 11706401 Review
4. GD Yancopoulos S Davis NW Gale JS Rudge SJ Wiegand J Holash 2000 Vascular-specific growth factors and blood vessel formation Nature 407 242 248 10.1038/35025215 1:CAS:528:DC%2BD3cXmvVSlsrY%3D 11001067 Review
5. P Carmeliet 2000 Mechanisms of angiogenesis and arteriogenesis Nat Med 6 389 395 10.1038/74651 1:CAS:528:DC%2BD3cXisVOrur4%3D 10742145 Review
6. AL Harris 2002 Hypoxia-a key regulatory factor in tumour growth Nat Rev Cancer 2 38 47 10.1038/nrc704 1:CAS:528:DC%2BD38XhvF2jtL4%3D 11902584 Review
7. BP Eliceiri DA Cheresh 1998 The role of alphav integrins during angiogenesis Mol Med 4 741 750 1:CAS:528:DyaK1MXhvFyisr8%3D 9990860 Review
8. RO Hynes BL Bader K Hodivala-Dilke 1999 Integrins in vascular development Braz J Med Biol Res 32 501 510 10.1590/S0100-879X1999000500002 1:CAS:528:DyaK1MXjvVKnu7w%3D 10412560 Review
9. MS Pepper 2001 Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis Arterioscler Thromb Vasc Biol 21 1104 1117 10.1161/hq0701.093685 1:CAS:528:DC%2BD3MXltlamur8%3D 11451738 Review
10. WP Leenders B Küsters RM de Waal 2002 Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis Endothelium 9 83 87 10.1080/10623320212006 12200959
11. N Ferrara 2005 The role of VEGF in the regulation of physiological and pathological angiogenesis EXS 94 209 231 15617481 Review
12. KA Houck N Ferrara J Winer G Cachianes B Li DW Leung 1991 The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA Mol Endocrinol 5 1806 1814 10.1210/mend-5-12-1806 1:CAS:528:DyaK3sXitVGrtLk%3D 1791831
13. E Tischer R Mitchell T Hartman M Silva D Gospodarowicz JC Fiddes, et al. 1991 The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing J Biol Chem 266 11947 11954 1:CAS:528:DyaK38XhtVSgtbk%3D 1711045
14. Z Poltorak T Cohen R Sivan Y Kandelis G Spira I Vlodavsky, et al. 1997 VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix J Biol Chem 272 7151 7158 10.1074/jbc.272.11.7151 1:CAS:528:DyaK2sXhvFKis7Y%3D 9054410
15. L Jingjing Y Xue N Agarwal RS Roque 1999 Human Müller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor Invest Ophthalmol Vis Sci 40 752 759 1:STN:280:DyaK1M7msFejsQ%3D%3D 10067980
16. T Lange N Guttmann-Raviv L Baruch M Machluf G Neufeld 2003 VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells J Biol Chem 278 17164 17169 10.1074/jbc.M212224200 1:CAS:528:DC%2BD3sXjsVKmsr0%3D 12598527
17. DO Bates TG Cui JM Doughty M Winkler M Sugiono JD Shields, et al. 2002 VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 4123 4131 1:CAS:528:DC%2BD38XlsV2ltrw%3D 12124351
18. J Plouët H Moukadiri 1990 Characterization of the receptor to vasculotropin on bovine adrenal cortex-derived capillary endothelial cells J Biol Chem 265 22071 22074 2266109
19. N Vaisman D Gospodarowicz G Neufeld 1990 Characterization of the receptors for vascular endothelial growth factor J Biol Chem 265 19461 19466 1:CAS:528:DyaK3cXlvVGgtr4%3D 2246236
20. LB Jakeman J Winer GL Bennett CA Altar N Ferrara 1992 Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues J Clin Invest 89 244 253 10.1172/JCI115568 1:CAS:528: DyaK38XnslWlsg%3D%3D 1729274
21. LB Jakeman M Armanini HS Phillips N Ferrara 1993 Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis Endocrinology 133 848 859 10.1210/en.133.2.848 1:CAS:528:DyaK3sXmtFyhu74%3D 7688292
22. N Ferrara T Davis-Smyth 1997 The biology of vascular endothelial growth factor Endocr Rev 18 4 25 10.1210/er.18.1.4 1:CAS:528:DyaK2sXhsFCiu7s%3D 9034784 Review
23. M Shibuya S Yamaguchi A Yamane T Ikeda A Tojo H Matsushime, et al. 1990 Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family Oncogene 5 519 524 1:CAS:528:DyaK3cXmtVGku74%3D 2158038
24. W Matthews CT Jordan M Gavin NA Jenkins NG Copeland IR Lemischka 1991 A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit Proc Natl Acad Sci U S A 88 9026 9030 10.1073/pnas.88.20.9026 1:CAS:528:DyaK3sXhslaisg%3D%3D 1717995
25. BI Terman ME Carrion E Kovacs BA Rasmussen RL Eddy TB Shows 1991 Identification of a new endothelial cell growth factor receptor tyrosine kinase Oncogene 6 1677 1683 1:CAS:528:DyaK3MXmslahsrc%3D 1656371
26. BI Terman M Dougher-Vermazen ME Carrion D Dimitrov DC Armellino D Gospodarowicz, et al. 1992 Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem Biophys Res Commun 187 1579 1586 10.1016/0006-291X(92)90483-2 1:CAS:528:DyaK3sXltV2lu7k%3D 1417831
27. TP Quinn KG Peters C De Vries N Ferrara LT Williams 1993 Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium Proc Natl Acad Sci U S A 90 7533 7537 10.1073/pnas.90.16.7533 1:CAS:528:DyaK3sXmsVWqsLY%3D 8356051
28. B Millauer S Wizigmann-Voos H Schnürch R Martinez NP Møller W Risau, et al. 1993 High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis Cell 72 835 846 10.1016/0092-8674(93)90573-9 1:CAS:528:DyaK3sXks1egsb8%3D 7681362
29. M Shibuya L Claesson-Welsh 2006 Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp Cell Res 312 549 560 10.1016/j.yexcr.2005.11.012 1:CAS:528:DC%2BD28XhvVWltbo%3D 16336962
30. S Li M Peck-Radosavljevic E Koller F Koller K Kaserer A Kreil, et al. 2001 Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy Int J Cancer 91 789 796 10.1002/1097-0215(200002)9999:9999<::AID- IJC1126>3.0.CO;2-K 1:CAS:528:DC%2BD3MXhsFGjtr8%3D 11275981
31. S Li M Peck-Radosavljevic O Kienast J Preitfellner G Hamilton A Kurtaran, et al. 2003 Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy Ann Oncol 14 1274 1277 10.1093/annonc/mdg344 1:STN:280:DC%2BD3szkvVaqtQ%3D%3D 12881392
32. S Li M Peck-Radosavljevic O Kienast J Preitfellner E Havlik W Schima, et al. 2004 Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma Q J Nucl Med Mol Imaging 48 198 206 1:STN:280:DC%2BD2crivVejsg%3D%3D 15499293
33. M Yoshimoto S Kinuya A Kawashima R Nishii K Yokoyama K Kawai 2006 Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model Nucl Med Biol 33 963 969 10.1016/j.nucmedbio.2006.08.006 1:CAS:528: DC%2BD28Xht1Cls7%2FL 17127168
34. FG Blankenberg S Mandl YA Cao C O'Connell-Rodwell C Contag C Mari, et al. 2004 Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor J Nucl Med 45 1373 1380 1:CAS:528: DC%2BD2cXnsFSmu7s%3D 15299064
35. FG Blankenberg MV Backer Z Levashova V Patel JM Backer 2006 In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF Eur J Nucl Med Mol Imaging 33 841 848 10.1007/s00259-006-0099-1 16699765
36. C Chan J Sandhu A Guha DA Scollard J Wang P Chen, et al. 2005 A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis J Nucl Med 46 1745 1752 1:CAS:528:DC%2BD28XitVGlt7k%3D 16204726
37. LG Presta H Chen SJ O'Connor V Chisholm YG Meng L Krummen, et al. 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599 1:CAS:528:DyaK2sXmslKqtLg%3D 9377574
38. WB Nagengast EG de Vries GA Hospers NH Mulder JR de Jong H Hollema, et al. 2007 In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft J Nucl Med 48 1313 1319 10.2967/jnumed.107.041301 1:CAS:528:DC%2BD2sXhtVSktb%2FE 17631557
39. TH Stollman MG Scheer WP Leenders KC Verrijp AC Soede WJ Oyen, et al. 2008 Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody Int J Cancer 122 2310 2314 10.1002/ijc.23404 1:CAS:528:DC%2BD1cXkslyntrY%3D 18240146
40. Nagengast WB, Lub-de Hooge MN, Hospers GA, Brouwers AH, Hoekstra HJ, Elsinga PH, et al. Towards clinical VEGF imaging using the anti-VEGF antibody bevacizumab and Fab-fragment ranibizumab. J Clin Oncol 2008;26: Abstract 3547.
41. J Folkman 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 27 31 10.1038/nm0195-27 1:CAS:528:DyaK2MXjs1KnsLk%3D 7584949
42. D Cheresh 1993 Integrins: structure, function and biological properties Adv Mol Cell Biol 6 225 10.1016/S1569-2558(08)60204-0
43. M Aumailley M Gurrath G Müller J Calvete R Timpl H Kessler 1991 Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett 291 50 54 10.1016/0014-5793(91)81101-D 1:CAS:528:DyaK38XisVGh 1718779
44. M Gurrath G Müller H Kessler M Aumailley R Timpl 1992 Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides Eur J Biochem 210 911 921 10.1111/j.1432-1033.1992.tb17495.x 1:CAS:528:DyaK3sXltFylsg%3D%3D 1483474
45. R Haubner R Gratias B Diefenbach S Goodman A Jonczyk H Kessler 1996 Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alphavbeta3 antagonists J Am Chem Soc 118 7461 7472 10.1021/ja9603721 1:CAS:528:DyaK28XksFKhtrc%3D
46. R Haubner H-J Wester U Reuning R Senekowitsch-Schmidtke B Diefenbach H Kessler, et al. 1999 Radiolabeled alphavbeta3 integrin antagonists: a new class of tracers for tumor targeting J Nucl Med 40 1061 1071 1:CAS:528: DyaK1MXktVaqsLg%3D 10452325
47. R Haubner H-J Wester F Burkhart R Senekowitsch-Schmidtke W Weber S Goodman, et al. 2001 Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 326 336 1:CAS:528:DC%2BD3MXhtlKmt7w%3D 11216533
48. R Haubner B Kuhnast C Mang W Weber H Kessler H-J Wester, et al. 2004 [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates Bioconjug Chem 15 61 69 10.1021/bc034170n 1:CAS:528: DC%2BD3sXpslWns7Y%3D 14733584
49. PM van Hagen WA Breeman HF Bernard M Schaar CM Mooij A Srinivasan, et al. 2000 Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy Int J Cancer 90 186 198 10.1002/1097-0215(20000820)90: 4<186::AID-IJC2>3.0.CO;2-P 10993959
50. N Assa-Munt X Jia P Laakkonen E Ruoslahti 2001 Solution structures and integrin binding activities of an RGD peptide with two isomers Biochemistry 40 2373 2378 10.1021/bi002101f 1:CAS:528:DC%2BD3MXnsFKjtQ%3D%3D 11327857
51. ZF Su G Liu S Gupta Z Zhu M Rusckowski DJ Hnatowich 2002 In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging Bioconjug Chem 13 561 570 10.1021/bc0155566 1:CAS:528:DC%2BD38XivFCgsb8%3D 12009947
52. ZF Su J He M Rusckowski DJ Hnatowich 2003 In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands Nucl Med Biol 30 141 149 10.1016/S0969-8051(02)00390-6 1:CAS:528:DC%2BD3sXhs1Clu7k%3D 12623113
53. GB Sivolapenko D Skarlos D Pectasides E Stathopoulou A Milonakis G Sirmalis, et al. 1998 Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide Eur J Nucl Med 25 1383 1389 10.1007/s002590050312 1:CAS:528:DyaK1cXmtFegt78%3D 9818277
54. B Costopoulos AD Varvarigou G Sivolapenko S Potamianos F Scopinaro SC Archimandritis 1997 Radiochemical and radiobiological evaluation of a synthetic peptide labelled with 99Tcm Nucl Med Commun 18 474 10.1097/00006231-199705000- 00058
55. ML Lindsey GP Escobar LW Dobrucki DK Goshorn S Bouges JT Mingoia, et al. 2006 Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction Am J Physiol Heart Circ Physiol 290 H232 H239 10.1152/ajpheart.00457.2005 1:CAS:528:DC%2BD28XhsVKjurk%3D 16126817
56. J Hua L Dobrucki M Sadeghi J Zhang B Bourke P Cavaliere, et al. 2005 Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia Circulation 111 3255 3260 10.1161/CIRCULATIONAHA.104.485029 1:CAS:528:DC%2BD2MXltVKmsbc%3D 15956134
57. T Bach-Gansmo TV Bogsrud A Skretting 2008 Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692 Clin Physiol Funct Imaging 28 235 239 10.1111/j.1475-097X.2008.00801.x 18384623
58. T Bach-Gansmo R Danielsson A Saracco B Wilczek TV Bogsrud A Fangberget, et al. 2006 Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692 J Nucl Med 47 1434 1439 1:CAS:528:DC%2BD28XhtVCmtLbP 16954550
59. R Axelsson T Bach-Gansmo J Castell-Conesa BJ McParland Study Group 2010 An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692 Acta Radiol 51 40 46 10.3109/02841850903273974 20001475
60. M Janssen WJ Oyen LF Massuger C Frielink I Dijkgraaf DS Edwards, et al. 2002 Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting Cancer Biother Radiopharm 17 641 646 10.1089/108497802320970244 1:CAS:528:DC%2BD3sXovVWmug%3D%3D 12537667
61. TM Behr DM Goldenberg W Becker 1998 Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations Eur J Nucl Med 25 201 212 10.1007/s002590050216 1:CAS:528:DyaK1cXhtVWisLw%3D 9473271 Review
62. ML Janssen WJ Oyen I Dijkgraaf LF Massuger C Frielink DS Edwards, et al. 2002 Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model Cancer Res 62 6146 6151 1:CAS:528:DC%2BD38XosF2ms7w%3D 12414640
63. I Dijkgraaf JA Kruijtzer S Liu AC Soede WJ Oyen FH Corstens, et al. 2007 Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides Eur J Nucl Med Mol Imaging 34 267 273 10.1007/s00259-006-0180-9 1:CAS:528:DC%2BD2sXnvVSgsA%3D%3D 16909226
64. D Boturyn JL Coll E Garanger MC Favrot P Dumy 2004 Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis J Am Chem Soc 126 5730 5739 10.1021/ja049926n 1:CAS:528:DC%2BD2cXivFems70%3D 15125666
65. I Dijkgraaf AY Rijnders A Soede AC Dechesne GW van Esse AJ Brouwer, et al. 2007 Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes Org Biomol Chem 5 935 944 10.1039/b615940k 1:CAS:528:DC%2BD2sXisV2gt7Y%3D 17340009
66. L Wang J Shi YS Kim S Zhai B Jia H Zhao, et al. 2009 Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers Mol Pharm 6 231 245 10.1021/mp800150r 1:CAS:528:DC%2BD1cXhsVOmt77I 19067525
67. J Shi L Wang YS Kim S Zhai Z Liu X Chen, et al. 2008 Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers J Med Chem 51 7980 7990 10.1021/jm801134k 1:CAS:528:DC%2BD1cXhsVKlu73K 19049428
68. Shi J, Kim YS, Chakraborty S, Zhou Y, Wang F, Liu S. Impact of bifunctional chelators on biological properties of (111)In-labeled cyclic peptide RGD dimers. Amino Acids 2010 Jan 6. [Epub ahead of print].
69. A Pini F Viti A Santucci B Carnemolla L Zardi P Neri, et al. 1998 Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel J Biol Chem 273 21769 21776 10.1074/jbc.273.34.21769 1:CAS:528:DyaK1cXlsFOqsL8%3D 9705314
70. S Demartis L Tarli L Borsi L Zardi D Neri 2001 Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin Eur J Nucl Med 28 534 539 10.1007/s002590100480 1:CAS:528:DC%2BD3MXktF2rsro%3D 11357506
71. M Santimaria G Moscatelli GL Viale L Giovannoni G Neri F Viti, et al. 2003 Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer Clin Cancer Res 9 571 579 1:CAS:528:DC%2BD3sXhtVKksrs%3D 12576420
72. D Berndorff S Borkowski D Moosmayer F Viti B Müller-Tiemann S Sieger, et al. 2006 Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments J Nucl Med 47 1707 1716 1:CAS:528:DC%2BD28XhtFKjtrbE 17015908
73. VU Chengazi MR Feneley D Ellison M Stalteri A Granowski M Granowska, et al. 1997 Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351) J Nucl Med 38 675 682 1:STN:280:DyaK2szhsVSrtg%3D%3D 9170426
74. SS Chang DS O'Keefe DJ Bacich VE Reuter WD Heston PB Gaudin 1999 Prostate-specific membrane antigen is produced in tumor-associated neovasculature Clin Cancer Res 5 2674 2681 1:CAS:528:DyaK1MXntlGltLw%3D 10537328
75. SS Chang VE Reuter WD Heston NH Bander LS Grauer PB Gaudin 1999 Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res 59 3192 3198 1:CAS:528:DyaK1MXksVCqtbs%3D 10397265
76. MJ Morris CR Divgi N Pandit-Taskar M Batraki N Warren A Nacca, et al. 2005 Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer Clin Cancer Res 11 7454 7461 10.1158/1078-0432.CCR-05-0826 1:CAS:528: DC%2BD2MXhtFartbvK 16243819
77. MJ Morris N Pandit-Taskar CR Divgi S Bender JA O'Donoghue A Nacca, et al. 2007 Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors Clin Cancer Res 13 2707 2713 10.1158/1078-0432.CCR-06-2935 1:CAS:528:DC%2BD2sXkslOhur0%3D 17473203